Overview
Taro Shibata practices in Tokyo, Japan. Mr. Shibata is rated as an Experienced expert by MediFind in the treatment of Nasopharyngeal Carcinoma. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Cervical Cancer, Colonoscopy, and Mastectomy.
His clinical research consists of co-authoring 100 peer reviewed articles. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Nasopharyngeal Carcinoma.
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Advanced
- Cervical CancerMr. Shibata isAdvanced. Learn about Cervical Cancer.
- Lung CancerMr. Shibata isAdvanced. Learn about Lung Cancer.
- Non-Small Cell Lung Cancer (NSCLC)Mr. Shibata isAdvanced. Learn about Non-Small Cell Lung Cancer (NSCLC).
- Small Cell Lung Cancer (SCLC)Mr. Shibata isAdvanced. Learn about Small Cell Lung Cancer (SCLC).
- Experienced
- Adult Soft Tissue SarcomaMr. Shibata isExperienced. Learn about Adult Soft Tissue Sarcoma.
- Alveolar Soft Part SarcomaMr. Shibata isExperienced. Learn about Alveolar Soft Part Sarcoma.
- AngiosarcomaMr. Shibata isExperienced. Learn about Angiosarcoma.
- B-Cell LymphomaMr. Shibata isExperienced. Learn about B-Cell Lymphoma.
- Bladder CancerMr. Shibata isExperienced. Learn about Bladder Cancer.
- Breast CancerMr. Shibata isExperienced. Learn about Breast Cancer.